In Brief: Ohmeda nitric oxide
Ohmeda nitric oxide: Oct. 23 review by FDA Cardiovascular & Renal Drugs Advisory Committee has been canceled. Ohmeda withdrew the nitric oxide NDA (20-845) for treatment of primary pulmonary hypertension in newborns and plans to resubmit it in 1998. Instead, the committee will discuss basic statistical considerations for evaluation of active-controlled clinical trials in the morning and meet in closed session during the afternoon. The Oct. 24 review of Sanofi/Bristol's Plavix will proceed as scheduled ("The Pink Sheet" Sept. 22, In Brief)...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth